Overview

Effects of Vildagliptine and Glimepiride on Glucose Variability

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to analyze the differences of blood sugar level and glycemic variability between sulfonylurea and DPP-4 inhibitor groups applying CGMS for a chosen number of type 2 DM patients. The investigators also reveal influences of each drugs on cardiovascular risk factors by measuring related biomarkers.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Glimepiride
Vildagliptin